Vertex Pharmaceuticals has grown revenue 9.8% a year over three years and 14% a year over five, with earnings per share compounding at 9.9%. Revenue growth, 3-year annual rate: +9.8% (Biotechnology median +17%). Revenue growth, 5-year rate: +14%, growth has slowed since the five-year average. Earnings per share, 3-year rate: +9.9%, earnings outgrew revenue: margins or the share count worked for shareholders. Years of annual history on file: 18, FY2008 to FY2025, as filed.

VRTXVertex Pharmaceuticals

Healthcare

$510.18+32% 1Y

$510.18

$376.6252 weeks$558.12

Is it growing?

Excellent

Growing: revenue growing +10% year on year, earnings up +22% year on year, and operating margin widening (+3.7 points).

3 good

Revenue trend+10% in a year

Trailing-twelve-month revenue vs a year earlier, from the company's own filings. Five-year pace: +13% a year.

Earnings trend+22% in a year

Trailing-twelve-month earnings per share against a year earlier. Growing faster than revenue, so margins or the share count are helping.

Margin direction+3.7 points operating

Trailing-twelve-month operating margin, 38.0% now against 34.3% a year earlier.

All from SEC EDGAR, as of Jun 30, 2026.

Against the whole market›

Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.

Revenue growth, 3 yearsbetter than 66% of the market

Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.

Is VRTX growing?

Vertex Pharmaceuticals has grown revenue 9.8% a year over three years and 14% a year over five, with earnings per share compounding at 9.9%.

+9.8%

Revenue growth, 3-year annual rate · Biotechnology median +17% · steady growth, ahead of inflation · compounded from trailing twelve-month revenue

Revenue growth, 5-year rate: +14%
Revenue growth, 5-year rate · +9.8% over three · growth has slowed since the five-year average
Earnings per share, 3-year rate: +9.9%
Earnings per share, 3-year rate · revenue +9.8% · earnings outgrew revenue: margins or the share count worked for shareholders
Years of annual history on file: 18
Years of annual history on file · FY2008 to FY2025, as filed